| 0.75 -0.091 (-10.82%) | 05-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.48 |
1-year : | 1.86 |
| Resists | First : | 1.26 |
Second : | 1.6 |
| Pivot price | 0.89 |
|||
| Supports | First : | 0.73 |
Second : | 0.6 |
| MAs | MA(5) : | 0.82 |
MA(20) : | 0.92 |
| MA(100) : | 1.06 |
MA(250) : | 1.23 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11  |
D(3) : | 9.4 |
| RSI | RSI(14): 30.4 |
|||
| 52-week | High : | 2.58 | Low : | 0.73 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ADGM ] has closed below the lower bollinger band by 6.9%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 23.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.85 - 0.86 | 0.86 - 0.86 |
| Low: | 0.72 - 0.73 | 0.73 - 0.73 |
| Close: | 0.74 - 0.75 | 0.75 - 0.76 |
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Thu, 21 May 2026
Adagio Medical (ADGM) files FDA PMA for vCLAS ventricular tachycardia ablation system - Stock Titan
Sun, 17 May 2026
Adagio Medical Holdings' US$2.5m Market Cap Fall Books Insider Losses - Sahm
Tue, 12 May 2026
Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress - ChartMill
Tue, 12 May 2026
Adagio Medical (NASDAQ: ADGM) posts Q1 2026 loss, highlights -VT trial and PMA plans - Stock Titan
Tue, 12 May 2026
Adagio Medical Holdings, Inc. 1Q 2026: Revenue $5.2M, EPS ($0.31) — 10-Q Summary - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 22 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 42.8 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 24 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -30.6 % |
| Return on Equity (ttm) | -268.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.85 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.57 |
| PEG Ratio | 0 |
| Price to Book value | 2.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|